Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)

PURPOSE: To evaluate secondary outcomes including changes in functioning and disability associated with galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, in patients with chronic migraine. METHODS: Patients randomly received galcanezumab (120 mg n = 278, 240 mg n = 27...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, Janet, Tassorelli, Cristina, Leroux, Elizabeth, Wang, Shufang, Ayer, David, Nichols, Russell, Detke, Holland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847867/
https://www.ncbi.nlm.nih.gov/pubmed/32930994
http://dx.doi.org/10.1007/s11136-020-02623-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847867/
https://www.ncbi.nlm.nih.gov/pubmed/32930994
http://dx.doi.org/10.1007/s11136-020-02623-1

Ejemplares similares